new oral glp 1 agonist GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is Lilly is now pharma's top

Position paper: single-dose activated charcoal

Heres the research physicians should know: Liew et al., 2014 (JAMA Pediatrics) risk ADHD/hyperkinetic disorders Brandlistuen et al., 2013 (IJE, MoBa Norway) Long-term use psychomotor & behavioral problems Avella-Garca et al., 2016 (IJE, Spain) ASD symptoms in boys, attention issues in both sexes Bornehag et al., 2018 (EHP, Sweden) Language delay in girls Ji et al., 2019 (JAMA Psychiatry) Cord blood biomarkers dose-response risk for ADHD & ASD Baker et al., 2020 (JAMA Pediatrics) Meconium biomarkers ADHD risk & altered brain connectivity Sznajder et al., 2022 (PLOS One) Use linked with neurobehavioral problems at 3 years Woodbury et al., 2024 (Pediatric Research / JDBP) Dose-response

L., Dear, J

La prsence de glutathion est indispensable pour une quantit importante de ractions physiologiques comme la dfense antioxydante (limination des radicaux libres), le mtabolisme de certains nutriments, la rgulation de la synthse de lADN et des protines, la prolifration cellulaire, lapoptose, la transduction du signal ou encore la rponse du systme immunitaire